PALO ALTO, Calif.--(BUSINESS WIRE)--Receptor BioLogix, Inc., today announced that a new publication in the journal Molecular Cancer Therapeutics1 confirms the broad anti-cancer potential of its pan-HER (human EGF receptor) ligand traps, which are novel fusion proteins designed to significantly improve the response rate and increase the survival of patients with HER-related cancers. These preclinical studies confirm that the company’s pan-HER ligand traps can successfully sequester multiple tumor promoting HER ligands and achieve a range of anti-tumor effects. Based on these positive results, Receptor BioLogix researchers have developed optimized pan-HER ligand traps that are now in pre-IND development.
